GC Genome earns money by providing customers with genome-analysis services that read out the genetic information of people and organisms, recognizing revenue at the point the work is completed; taking in a sample, analyzing the genetic information, and handing over the result is its core revenue source. A January 2026 disclosure reported 2025 revenue of ₩31.5 billion, operating profit of ₩1.2 billion, and net profit of ₩4.0 billion, breaking two years of losses and turning positive, and the May quarterly report showed the recovery continuing with Q1 revenue of ₩7.4 billion, operating profit of ₩100 million, and net profit of ₩800 million. What stands out recently is that, alongside the turn to profit, revenue and earnings are rising and the P/E is lower than adjacent names (in the 50-62x range), so it is on the cheaper side relative to earnings; on the other hand, net profit exceeds operating profit, indicating some reliance on non-operating items, and with a small market cap, disclosures such as a capital increase or the exercise of conversion rights can have a large effect on the share count and the metrics.
At-a-glance assessment financial health · growth · profitability · valuation
- Debt ratio, current ratio and interest burden all look healthy.
- Revenue rose 21.8% year over year, and the pace is quickening (3-year trend: mixed).
- Net profit swung from a loss a year earlier back into the black (a turnaround).
- Most recent quarter (Q1 2026) revenue was 9.1% higher than a year earlier.
- ROE is 5.2% (total-net basis). It is above the sector average.
- Operating margin is 3.9%.
- The P/E sits below the sector median.
Ownership & governance As of 2025-12-31
Largest shareholder GC Biopharma 19.6% (corporate)
Controlling bloc incl. related parties 42.57%
With the controlling bloc holding 43%, the ownership structure is stable.
🔎 In-depth analysis
- GC Genome is a company whose mainstay is genome (the genetic information of people and organisms) analysis.
- It provides genome-analysis services to customers and recognizes the agreed amount as revenue at the point the work is completed.
- In other words, its core revenue source is the service of taking in a sample, reading out the genetic information, and handing over the result.
- As a name with a not-large market capitalization of ₩104.4 billion, it is worth watching not only the flow of the business itself but also the effect each disclosure has on results and the share count.
- The latest close is ₩4,525 and market capitalization is ₩107.0 billion.
- The price sits below the 20-day line (₩4,852) and below the 60-day line (₩6,323).
- Trading below both its short- and mid-term moving averages, the trend is on the subdued side.
- RSI (an auxiliary gauge that scores upward versus downward momentum over the past 14 days on a 0-100 scale) is 34.3, at a neutral level.
- The one-month change is -10.9%, the three-month change is -35.8%, and the position versus the 52-week high is -51.4%.
- Relative strength versus the KOSDAQ is 45 (1-99, computed from returns against the index over the past year with more weight on recent performance; higher means stronger than the market).
- This places it in roughly the top 55% of all stocks by strength.
- Over the past three months it lagged the index by 15.6%.
- Chart reading is best done alongside trading volume and disclosure dates.
- 2025 revenue was ₩31.5 billion, operating profit ₩1.2 billion, and net profit ₩4.0 billion.
- The operating margin is 3.9%, and ROE (how much is earned per year on equity) is 5.2%, above the sector average.
- The debt ratio (debt versus equity) is 108.1%, but the current ratio is very high (current assets are more than 18 times the debt due within a year), so short-term funding is ample, and the diagnostic financial soundness is "stable." The P/E ratio (how many times one year's earnings the share price is) is 26.46x and P/B (how many times book value the share price is) is 1.37x.
- On the numbers alone the P/E may not look low, but set against the 50-62x P/E of adjacent names in the same sector it is on the lower side, so the diagnosis is "undervalued." One point to note is that net profit (₩4.0 billion) exceeds operating profit (₩1.2 billion), a result of non-operating items being added, so the quality of earnings is more accurately gauged by also watching whether the operating margin climbs.
- Revenue was ₩27.3 billion in 2023, ₩25.9 billion in 2024, and ₩31.5 billion in 2025, rising 21.8% last year to return to growth.
- The more important change is in earnings.
- Net profit was a loss for two years—-₩550 million in 2023 and -₩1.26 billion in 2024—before turning positive at +₩4.0 billion in 2025.
- Operating profit likewise flipped from a -₩1.2 billion loss in 2024 to +₩1.2 billion in 2025.
- The most recent quarter (Q1 2026) also saw revenue rise 9.1% year on year to ₩7.4 billion, with net profit up 174% year on year to ₩800 million, so the recovery is continuing.
- That said, no official company full-year guidance for this year could be confirmed, so here we rely only on confirmed results and the quarterly trend.
- As it has just turned from loss to profit, the key is to confirm each quarter whether the earnings scale settles in.
- On 2026-01-19, a disclosure of a revenue/profit-structure change of 30% or more reported 2025 full-year revenue of ₩31.5 billion, operating profit of ₩1.2 billion, and net profit of ₩4.0 billion.
- Given that the prior two years were losses, this is material signaling a turn to profit, and it is worth checking whether it moves in the same direction as the annual trend and whether one-off factors are mixed in.
- Next, the 2026-05-15 quarterly report confirmed Q1 2026 revenue of ₩7.4 billion, operating profit of ₩100 million, and net profit of ₩800 million, with the recovery continuing.
- The 2026-03-16 annual business report (2025.12) contains the confirmed full-year results and serves as a benchmark for cross-checking whether they match the earlier provisional figures in direction.
- The strengths are clear.
- After ending two years of losses, both operating and net profit turned positive in 2025, and revenue and earnings have kept rising together through the most recent quarter, so the recovery continues.
- The P/E is also lower than adjacent names in the same sector (in the 50-62x range), so the share price is on the cheaper side relative to earnings, and the financial structure viewed on a liquidity basis is stable.
- The share price is down more than half from its 52-week high with RSI in depressed territory, so if recovery results are confirmed each quarter, the lowered price could become a strength.
- The points to be careful about are that net profit exceeds operating profit, indicating some reliance on non-operating items, and that with a small market cap, funding-related disclosures such as a capital increase or the exercise of conversion rights can have a large effect on the share count and the metrics.
- In sum, this is a stock underpinned by a turn to profit and a low P/E, strong when the operating margin keeps climbing and quarterly results continue, and prone to wobble when non-operating gains shrink or financing disclosures overlap.
🔎 Valuation vs peers Undervalued
A peer set within professional and technical services that is adjacent by market capitalization.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Grid Wiz | 45.79x | 0.74x | 1.61% |
| Macrogen | 62.50x | 0.81x | 1.29% |
| I-Tech | — | 0.84x | -2.69% |
Within professional and technical services, we first looked at a public-data peer set close by market capitalization. The current P/E ratio (how many times one year's earnings the share price is) is 26.46x and P/B (how many times book value the share price is) is 1.37x. That said, for lower-market-cap names, earnings swings and financing disclosures carry a large effect, so we did not draw firm conclusions from metrics based on last year's confirmed results alone. The basis for the outlook box is that official company guidance cannot be confirmed.
Price history Close · MA20 · MA60
The latest close is ₩4,525 and the market capitalization is ₩107.0 billion. The price sits below its 20-day moving average (₩4,852) and below its 60-day moving average (₩6,323). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 34.3, a neutral level. The one-month change is -10.9%, the three-month change is -35.8%, and the position relative to the 52-week high is -51.4%. Relative strength versus the KOSDAQ is 45 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 45% of all stocks. Over the past three months it lagged the index by 15.6%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -15.61% / 6M -17.33% / 12M -48.45%
Key metrics vs sector median
Valuation
The P/E of 26.46x is below the sector median (44.74x). The P/B of 1.37x is in line with the sector median (1.26x). That said, this P/E is based on last year's (trailing) results. With recent quarterly earnings up sharply, the trailing P/E can look higher than it really is, so a precise read is best done on this year's expected (forward) earnings.
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Intrinsic value (DCF estimate)
DCF (discounted cash flow) estimate — discount rate 9.2%, initial growth 4.0%→terminal 2.0%, 10-yr forecast, free-cash-flow basis. A reference range that shifts materially with assumptions.
Profitability & financials
Return on equity (ROE) is 5.2%, above the sector average (2.0%). The operating margin is 3.9%. The debt ratio is 108.1%, so the financial structure is moderate.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $18.1M | $17.2M | $20.9M | +21.81% ↑ faster |
| Operating profit | $106,095 | -$817,532 | $818,934 | — |
| Net profit | -$364,589 | -$833,050 | $2.7M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $18.1M | $17.2M | $20.9M |
| Operating profit | — | — | $106,095 | -$817,532 | $818,934 |
| Net profit | — | — | -$364,589 | -$833,050 | $2.7M |
| Revenue CAGR | 2-yr avg 7.49% | ||||
Revenue rose 21.8% year over year (2023 ₩27.3 billion → 2024 ₩25.9 billion → 2025 ₩31.5 billion), and the three-year trend is 'mixed'. The pace of growth also quickened from the prior year. Over the 3 years on record, revenue compound annual growth (CAGR) is 7.5%. The two-year revenue CAGR is 7.5%. In the most recent quarter (Q1 2026), revenue was 9.1% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.
- Revenue grew 21.8% year over year, a sign of growth.
- The balance sheet is stable in terms of debt and liquidity.
Points to watch
- The figures shown are based on the last annual report as of the writing date, so it is best to review the latest quarterly results and filings alongside them.
Recent news & events searched · sourced
- 2026-01-19EarningsRevenue or profit-structure change of 30% or more (15% for large corporations): full-year revenue ₩31.5 billion, operating profit ₩1.2 billion, net profit ₩4.0 billionThis is the most recent confirmed or provisional results. Check whether it moves in the same direction as the annual trend and whether there are one-off factors. Source
- 2026-05-15EarningsQuarterly report (2026.03): Q1 2026 revenue ₩7.4 billion, operating profit ₩100 million, net profit ₩800 millionThis is the most recent confirmed or provisional results. Check whether it moves in the same direction as the annual trend and whether there are one-off factors. Source
- 2026-03-16EarningsAnnual business report (2025.12): revenue ₩260,000, operating profit ₩1.2 billion, net profit ₩4.0 billionThis is the most recent confirmed or provisional results. Check whether it moves in the same direction as the annual trend and whether there are one-off factors. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Closing price | ₩4,525 | ₩4,525 | Confirmed | link |
| Latest quarterly results | revenue ₩7.4 billion, operating profit ₩0.1 billion | revenue ₩7.4 billion, operating profit ₩0.1 billion | Confirmed | link |
| Annual results | revenue ₩31.5 billion, operating profit ₩1.2 billion | revenue ₩31.5 billion, operating profit ₩1.2 billion | Confirmed | link |
| Results disclosure original text | revenue30%: revenue ₩31.5 billion · operating profit ₩1.2 billion · net profit ₩4.0 billion | revenue30%: revenue ₩31.5 billion · operating profit ₩1.2 billion · net profit ₩4.0 billion | Confirmed | link |
| Results disclosure original text | (2026.03): 2026 1 revenue ₩7.4 billion · operating profit ₩0.1 billion · net profit ₩0.8 billion | (2026.03): 2026 1 revenue ₩7.4 billion · operating profit ₩0.1 billion · net profit ₩0.8 billion | Confirmed | link |
| Results disclosure original text | (2025.12): revenue 26 · operating profit ₩1.2 billion · net profit ₩4.0 billion | (2025.12): revenue 26 · operating profit ₩1.2 billion · net profit ₩4.0 billion | Confirmed | link |
| Outlook box basis | — | — | Unverified | — |
Recent filings
- 2026-05-15PeriodicQuarterly report
- 2026-03-24Shareholders' meeting notice
- 2026-03-16PeriodicAnnual business report
- 2026-03-16Audit report
- 2026-03-09Shareholders' meeting notice
- 2026-02-23Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.